Eyeing The Ear: Start-up Decibel Intends To Tackle Inner-Ear Indications
This article was originally published in Scrip
Executive Summary
Hearing indications represent a very underserved space for drug therapies, and even the companies that do participate often do so with just a single, isolated program or candidate. Third Rock Ventures thinks it will be able to build the "definitive" inner ear specialist, through internal R&D as well as licensing, with start-up Decibel Therapeutics, which announced a $52m Series A financing on Oct. 15.
You may also be interested in...
Novel Regeneron Deal Puts Partner Decibel In The Driver's Seat
Regeneron signed a unique agreement with the hearing-focused start-up Decibel in which it will make a minority equity investment and pay R&D costs, but leave full commercialization rights with its partner. The deal sprang from Regeneron’s outreach to venture-backed biotechs.
Finance Watch VC Edition: Biopharma Venture Investment Rises In Second Quarter
Venture capital investment in biopharmaceutical firms for the first half of 2017 show that this year is on track to exceed 2016 levels. Recent financings include two $50m Series C rounds for two different companies developing later-stage drugs for itching: Trevi and Menlo Therapeutics.
Travere Looks Ahead To Phase III In Homocystinuria
The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.